High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma

Histopathology
M M IndaJ S Castresana

Abstract

Medulloblastoma (MB) is the most common primitive neuroectodermal tumour (PNET) of the central nervous system. Although supratentorial PNET (sPNET) and MB are histologically similar, their clinical behaviour differs, sPNET being more aggressive than MB. The aim of this study was to determine whether sPNET and MB are genetically different entities. We investigated 32 PNET primary tumour samples (23 MB and nine sPNET) and four PNET cell lines, for the presence of CDKN2A homozygous deletions at exon 1-alpha of p16/INK4 and exon 1-beta of p14/ARF, and promoter hypermethylation of both genes. No homozygous deletion of either p16/INK4 or p14/ARF was demonstrated in any of the PNET primary tumour samples. Methylation of p16/INK4 was found in one of six sPNET and in one of 23 MB, while p14/ARF methylation was observed in three of six sPNET and in three of 21 MB. No methylation of p16/INK4 or p14/ARF was found in any of the PNET cell lines analysed. The three MB cell lines did not show p16/INK4 expression, and only the MB Daoy cell line (homozygously deleted at CDKN2A) presented loss of p14/ARF expression. Our results in this limited series of central PNET show that p14/ARF is frequently involved in PNET carcinogenesis, with a higher fr...Continue Reading

References

Jan 1, 1990·Acta Neuropathologica·D TroostK P Dingemans
Nov 1, 1989·Genes, Chromosomes & Cancer·J A BiegelB S Emanuel
Jan 1, 1988·Cancer Genetics and Cytogenetics·S H BignerD D Bigner
Sep 1, 1994·Cancer Genetics and Cytogenetics·E PruchonB Dutrillaux
Jan 1, 1993·Molecular Carcinogenesis·H OhgakiP Kleihues
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Jan 1, 1997·Journal of Neuro-oncology·F G BarkerM A Israel
Apr 17, 2001·Brain Pathology·M NakamuraH Ohgaki
Dec 6, 2003·Journal of Neuropathology and Experimental Neurology·Anke WahaTorsten Pietsch
Mar 19, 2004·Pathology Oncology Research : POR·Martin EbingerWolfram Scheurlen

❮ Previous
Next ❯

Citations

Oct 27, 2009·Brain Tumor Pathology·Hiroyuki Momota, Eric C Holland
Apr 29, 2010·Current Neurology and Neuroscience Reports·Adrian M DubucMichael D Taylor
Apr 25, 2007·Molecular and Cellular Biology·Dmitri WiederschainJohn D Benson
Aug 3, 2011·Journal of Neurosurgery. Pediatrics·Claudia M C FariaPaul Kongkham
Nov 2, 2012·Neuromolecular Medicine·Anastasia SpyropoulouAthanasios G Papavassiliou
Jan 26, 2008·The Journal of Investigative Dermatology·Anita LassacherPeter Wolf
Jan 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Sexton-OatesR Saffery
Jul 30, 2016·BMB Reports·Aram KoJaewhan Song

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.